Early Symptom Improvements With Risankizumab Induction Therapy and Their Association With Future Clinical and Endoscopic Outcomes in Patients With Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies
J Crohns Colitis 2024 Jun 03;18(6)818-827, JF Colombel, S Schreiber, G D'Haens, J Rizzo, K Kligys, J Griffith, J Zambrano, Q Zhou, Y Zhang, J Kalabic, F Rieder, MC Dubinsky, R PanaccioneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.